Ipca Laboratories Ltd (IPCALAB)
🎯 Key Takeaways
- IPCA Laboratories is in a clear phase of accelerated growth driven by strategic expansion, biosimilars development, and the integration of Krebs Biochemicals, supported by strong execution in domestic and export markets. Management has upgraded growth and margin targets, signaling confidence in sustainable profitability and long-term value creation.
- Revenue grew 16.7% QoQ to ₹2,788 in Q1FY27.
- ⚠️ Material cost inflation remains a near-term risk, with input costs up 21% despite cost control measures. Integration of Krebs Biochemicals carries exe
- Market Cap
- ₹48,712
- P/E Ratio
- 36.1
- P/B Ratio
- 6.04
- ROE
- 16.2%
- ROCE
- 21.5%
- Debt/Equity
- 0.09
- Div Yield
- 0.31%
- Promoter
- 44.7%
📖 The Story
IPCA Laboratories is in a clear phase of accelerated growth driven by strategic expansion, biosimilars development, and the integration of Krebs Biochemicals, supported by strong execution in domestic and export markets. Management has upgraded growth and margin targets, signaling confidence in sustainable profitability and long-term value creation.
📰 What's Happening
In Q1 FY27, IPCA delivered consolidated revenue of ₹2,308.85 crores (+21% YoY) and profit before tax of ₹572.08 crores, with management revising FY27 growth guidance to 14-16% from 12-13% and EBITDA margin to 22.88%. The Board approved the amalgamation of Krebs Biochemicals effective April 1, 2026, to enhance API supply and operational efficiency. Shareholders approved FY2026 audited financials and reappointed directors at the 76th AGM on August 13, 2026. A record date of August 7, 2026, was set for dividend entitlement ahead of the AGM, with a proposed dividend of ₹6 per share (600% of face value).
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 2,309 | 2,557 | 2,393 | 2,388 | 2,788 |
| Operating Profit | 316 | 442 | 426 | 377 | 559 |
| OPM % | 13.7% | 17.3% | 17.8% | 15.8% | 20.0% |
| Net Profit | 234 | 284 | 364 | 309 | 423 |
| EPS | ₹9.19 | ₹11.14 | ₹12.86 | ₹13.31 | ₹15.84 |
Revenue has grown consistently over the past five quarters, rising from ₹2,309 crores in Jun 2025 to ₹2,788 crores in Jun 2026, with a corresponding improvement in operating profit margin from 13.7% to 20.0%. Net profit and EPS have also expanded steadily, reflecting operational efficiency and scale benefits. This growth trajectory aligns with management’s upward revision in guidance, driven by strong formulation and export performance, as well as cost control measures offsetting 21% material cost inflation.
🔮 Management Outlook & What's Next
Management expects FY28 revenue growth of 14-16% and EBITDA margin expansion to 22-23% (up 1 percentage point), with long-term targets of 25% consolidated and 30% for IPCA specifically, supported by biosimilars and capacity investments. These targets are underpinned by R&D in seven pipeline candidates and synergies from the Krebs Biochemicals amalgamation, which is expected to enhance margins and supply chain resilience.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 |
| Reserves | 6,923 | 6,675 | 8,038 | 7,402 |
| Borrowings | 1,363 | 1,202 | 704 | 1,279 |
| Total Liabilities | 11,761 | 11,424 | 12,370 | 12,263 |
| Fixed Assets | 4,069 | 4,291 | 4,638 | 4,168 |
| Investments | 980 | 944 | 844 | 1,203 |
| Total Assets | 11,761 | 11,424 | 12,370 | 12,263 |
The balance sheet shows a deliberate reduction in net debt to ₹193 crores and stable equity base, indicating a conservative capital structure. Reserves have grown steadily to ₹8,038 crores, reflecting retained earnings and strategic reinvestment. Total assets have increased to ₹12,370 crores, supporting expansion plans in biosimilars and manufacturing, while maintaining low leverage (D/E of 0.09) to fund growth without overleveraging.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +1,142 |
| Investing | -247 |
| Financing | -754 |
| Net Cash Flow | +142 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 44.7% | 44.7% | 44.7% | 44.7% |
| FII | 10.4% | 10.6% | 10.6% | 10.7% |
| DII | 36.8% | 37.3% | 37.5% | 37.4% |
| Public | 6.5% | 5.9% | 5.8% | 5.8% |
| # Shareholders | 82,870 | 77,673 | 82,184 | 82,060 |
Institutional investor interest remains strong, with FII holding at 10.73% and DII at 37.37% in Q1FY27, up from 10.43% and 36.77% respectively in Q2FY26, indicating accumulation. The promoter holding remains stable at 44.72%, with a broad retail base (5.76% public) and 82,060 shareholders, reflecting broad-based confidence. No pledging or significant dilution was observed, suggesting stable ownership structure amid growth.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
Material cost inflation remains a near-term risk, with input costs up 21% despite cost control measures. Integration of Krebs Biochemicals carries execution risk, including operational harmonization and realization of synergies. Regulatory and pricing pressures in the domestic formulation market could impact margins. Additionally, while export growth is strong, foreign exchange volatility and global demand softness could affect international performance.
📋 Recent Filings
- Announcement2026-09-22Ipca Laboratories Ltd announced that its insider trading window will close on October 1, 2026, remaining shut until 48 hours after the unaudited Q2 re…
- 🔴 Financial Results2026-08-17IPCA Laboratories reported strong Q1 FY27 growth with domestic formulation revenue up 13% to INR1,082 crores and export revenue up 34% to INR603 crore…
- 🟡 Board Meeting2026-08-13IPCA Laboratories held its 76th Annual General Meeting on August 13, 2026 via video conference, adopting audited financial statements for FY2026, decl…
- 🟡 Board Meeting2026-08-13The Board approved unaudited Q1 FY27 results showing consolidated revenue of **₹2,308.85 crores** (up 21% YoY) and profit before tax of **₹572.08 cror…
- Announcement2026-08-06IPCA Laboratories announced a conference call on August 14, 2026 at 15:30 IST to discuss Q1FY27 earnings and business update, following the release of…
- 🔴 Corporate Action2026-07-14IPCA Laboratories announced a record date of August 7, 2026 for dividend entitlement tied to its upcoming AGM on August 13, 2026, with a proposed divi…
- share transfer2026-07-13IPCA Laboratories reported receipt of a SEBI-mandated certificate from its share transfer agent MUFG Intime India for the quarter ended June 30, 2026,…
- 🟡 concall transcript2026-06-30Ipca Laboratories reported strong Q1 FY27 growth with 13% revenue increase in India's formulation segment to INR1,082 crores and 34% export growth to …
- 🟡 Board Meeting2026-06-26The board approved the amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories, effective April 1, 2026, following all required ap…
- 🟡 Board Meeting2026-06-26The board approved the merger of Krebs Biochemicals & Industries into Ipca Laboratories, subject to regulatory approvals, with an effective date of Ap…
🧠 Analyst's Read
IPCA Laboratories is transitioning from a high-growth domestic player to a more diversified, margin-accretive enterprise with global ambitions, supported by strategic acquisitions, biosimilars, and disciplined capital allocation. Investors should monitor execution of the Krebs integration, biosimilars commercialization timeline, and management’s ability to sustain margin expansion amid cost pressures.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when IPCALAB files new disclosures
Track IPCALAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track IPCALAB — FreeFree account · 2 AI queries/day